![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to PRX3. It is being evaluated for the treatment of malignant pleural mesothelioma.
Lead Product(s): Thiostrepton
Therapeutic Area: Oncology Product Name: RSO-021
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2024
Details:
RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to mitochondrial peroxiredoxin 3 (PRX3). It is being evaluated in phase 2 clinical trials for the treatment of malignant pleural mesothelioma and metastatic disease to the lung.
Lead Product(s): Thiostrepton
Therapeutic Area: Oncology Product Name: RSO-021
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024